Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318005 · ClinicalTrials.gov registry record · NA
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT01318005: Completed NA study, sponsored by University of Southern California.
NCT01318005 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01318005, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of estrogen; this research will examine that in detail.
Primary Outcome
Percent of cells expressing staining for Ki67 will be examined in breast epithelial cells
Interventions
- DRUG Oral Contraceptive: Ortho-Novum® 1/35
- DRUG Oral Contraceptive: Ovcon® 35
- DRUG Oral Contraceptive: Microgestin Fe® 1/20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2011-02-14 |
| Est. Completion | 2015-06-30 |
| Phase | NA |
What the finished NCT01318005 record still lists
NCT01318005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Oral Contraceptive: Ortho-Novum® 1/35 is the first listed.
NCT01318005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01318005 about?
NCT01318005 is a clinical study titled "Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation". The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control...
What is the current status of trial NCT01318005?
This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 2011-02-14. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT01318005?
The interventions under investigation include: Oral Contraceptive: Ortho-Novum® 1/35 (DRUG), Oral Contraceptive: Ovcon® 35 (DRUG), Oral Contraceptive: Microgestin Fe® 1/20 (DRUG).
Who is sponsoring clinical trial NCT01318005?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01318005's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI